Successful Health Care Investment Executive
with Extensive Business, Scientific and Medical Knowledge, as well
as Broad Industry and Investment Experience
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX),
a clinical-stage biotechnology company developing novel cell
transplants for serious medical conditions, today announced the
appointment of Anula Jayasuriya, M.D., Ph.D., M.B.A., to the
Company’s Board of Directors, effective as of May 4, 2021. Dr.
Jayasuriya is a successful healthcare private equity executive and
venture capitalist with extensive clinical, industry,
entrepreneurial, and investment experience. Dr. Jayasuriya is the
Founder & Managing Director of EXXclaim Capital, an early-stage
venture fund focused on catalyzing innovation, entrepreneurship and
investment in Women’s Health, and a Co-founder of Evolvence India
Life Science Fund (EILSF), the first fund in India to focus
exclusively on healthcare and invest in Indian pharmaceutical,
biotechnology, medical device and contract services companies. Dr.
Jayasuriya received a B.A. from Harvard University summa cum laude,
a M. Phil. in pharmacology from the University of Cambridge, an
M.D. and Ph.D. (in Microbiology and Molecular Genetics) from
Harvard Medical School and an M.B.A. with distinction from Harvard
Business School.
“Dr. Jayasuriya is a successful healthcare investment executive
with deep insights and experience in the clinical development of a
wide range of medical products. We are delighted she will be
joining our Board of Directors,” stated Al Kingsley, Lineage’s
Chairman of the Board. “Dr. Jayasuriya’s appointment reflects an
overall commitment to ensuring that our Board reflects a broad
range of expertise and perspectives as Lineage works to position
itself as a leader in the field of cell therapy and regenerative
medicine.”
“I am excited to join Lineage’s Board at a transformational time
in the Company’s history,” stated Dr. Jayasuriya. “Lineage is
pioneering a new branch of medicine by advancing its off-the-shelf
cell transplant therapies toward later stage clinical trials. These
products have the potential to address multi-billion-dollar market
opportunities and greatly improve the lives of patients. I look
forward to helping the Company as it positions itself for success
in 2021 and beyond.”
Anula Jayasuriya, M.D., Ph.D.,
M.B.A.
Dr. Jayasuriya is the Founder & Managing Director of
EXXclaim Capital, an early-stage venture fund focused on catalyzing
innovation, entrepreneurship and investment in Women’s Health, and
a Co-founder of Evolvence India Life Science Fund (EILSF), the very
first fund in India to focus exclusively on health care and invest
in Indian pharmaceutical, biotechnology, medical device and
contract services companies. Dr. Jayasuriya has applied deep
business, scientific, and medical knowledge in her career as a
pharmaceutical company executive, private equity executive, and
venture capitalist, providing her with a broad experience base
spanning clinical, executive, entrepreneurial, and financial roles.
She was among the first investors to recognize the untapped
opportunity in the unmet needs in women’s health.
Integrating her passion with her investing expertise, in 2013
Dr. Jayasuriya founded EXXclaim Capital, which has invested in a
portfolio of diverse Women’s Health companies ranging from digital
health, medical devices, and diagnostics to consumer products.
EXXclaim’s first investment, nVision Medical, was acquired in 2018
by Boston Scientific Inc. In 2006, she co-founded EILSF, focusing
exclusively on investment in Indian pharmaceutical, biotechnology,
medical device and contract services companies. Dr. Jayasuriya was
previously a partner with Skyline Ventures in Palo Alto, and prior
to that with the German/US venture capital firm TVM, in San
Francisco. Her prior positions include VP Business Development at
Genomics Collaborative Inc., Vice President, Global Drug
Development at Hoffman-La Roche for opportunistic infections in
AIDS and Transplantation, and Director, Outcomes Research at Syntex
Laboratories.
Dr. Jayasuriya received a BA from Harvard summa cum laude, and
an MD and PhD (in Microbiology and Molecular Genetics) from Harvard
Medical School. She interned in Pediatrics at Boston Children’s
Hospital and received an MBA with distinction from Harvard Business
School. Dr. Jayasuriya also holds a M. Phil. in pharmacology from
the University of Cambridge, in England.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology
company developing novel cell therapies for unmet medical needs.
Lineage’s programs are based on its robust proprietary cell-based
therapy platform and associated in-house development and
manufacturing capabilities. With this platform Lineage develops and
manufactures specialized, terminally differentiated human cells
from its pluripotent and progenitor cell starting materials. These
differentiated cells are developed to either replace or support
cells that are dysfunctional or absent due to degenerative disease
or traumatic injury or administered as a means of helping the body
mount an effective immune response to cancer. Lineage’s clinical
programs are in markets with billion dollar opportunities and
include three allogeneic (“off-the-shelf”) product candidates: (i)
OpRegen®, a retinal pigment epithelium transplant therapy in Phase
1/2a development for the treatment of dry age-related macular
degeneration, a leading cause of blindness in the developed world;
(ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a
development for the treatment of acute spinal cord injuries; and
(iii) VAC, an allogeneic dendritic cell therapy platform for
immuno-oncology and infectious disease, currently in clinical
development for the treatment of non-small cell lung cancer. For
more information, please visit www.lineagecell.com or follow the
Company on Twitter @LineageCell.
Forward-Looking Statements
Lineage cautions you that all statements, other than statements
of historical facts, contained in this press release, are
forward-looking statements. Forward-looking statements, in some
cases, can be identified by terms such as “believe,” “may,” “will,”
“estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,”
“could,” “plan,” “potential,” “predict,” “seek,” “should,” “would,”
“contemplate,” project,” “target,” “tend to,” or the negative
version of these words and similar expressions. Such statements
include, but are not limited to, statements relating to Lineage
advancing its off-the-shelf cell transplant therapies toward later
stage clinical trials and the potential of those products to
address multi-billion-dollar market opportunities and greatly
improve the lives of patients and Lineage’s positioning for future
success. Forward-looking statements involve known and unknown
risks, uncertainties and other factors that may cause Lineage’s
actual results, performance or achievements to be materially
different from future results, performance or achievements
expressed or implied by the forward-looking statements in this
press release, including risks and uncertainties inherent in
Lineage’s business and other risks described in Lineage’s filings
with the Securities and Exchange Commission (SEC). Lineage’s
forward-looking statements are based upon its current expectations
and involve assumptions that may never materialize or may prove to
be incorrect. All forward-looking statements are expressly
qualified in their entirety by these cautionary statements. Further
information regarding these and other risks is included under the
heading “Risk Factors” in Lineage’s periodic reports with the SEC,
including Lineage’s most recent Annual Report on Form 10-K filed
with the SEC and its other reports, which are available from the
SEC’s website. You are cautioned not to place undue reliance on
forward-looking statements, which speak only as of the date on
which they were made. Lineage undertakes no obligation to update
such statements to reflect events that occur or circumstances that
exist after the date on which they were made, except as required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210505005261/en/
Lineage Cell Therapeutics, Inc. IR Ioana C. Hone
(ir@lineagecell.com) (442) 287-8963
Solebury Trout IR Gitanjali Jain Ogawa
(Gogawa@soleburytrout.com) (646) 378-2949
Russo Partners – Media Relations Nic Johnson or David
Schull Nic.johnson@russopartnersllc.com
David.schull@russopartnersllc.com (212) 845-4242
Lineage Cell Therapeutics (AMEX:LCTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Lineage Cell Therapeutics (AMEX:LCTX)
Historical Stock Chart
From Sep 2023 to Sep 2024